Engflag

Scheinpharm Ranitidine

Quick links to important sections

Scheinpharm Ranitidine

Scheinpharm Ranitidine_EN

Method of action: Antiulcer, Drugs For Acid Related Disorders

Treatment option: Duodenal Ulcer, Dyspepsia, Heartburn, Reflux, Reflux Esophagitis, Zollinger-Ellison Syndrome, Stress, Esophagitis, Erosive Esophagitis, Stomach Ulcer

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Scheinpharm Ranitidine

Quick Facts

Property Description
Active ingredient Ranitidine Hydrochloride
Form Tablet (Oral Dosage Form), Solution for Injection
Pharmacological class Histamine H2 (H2) receptor antagonist
Common purpose Reduction of gastric acid secretion
Origin Synthetic compound

What Type of Medicine is Scheinpharm Ranitidine?

Scheinpharm Ranitidine is a synthetic pharmaceutical preparation that belongs to the Histamine H2 receptor antagonist class, commonly known as an H2-blocker. The active ingredient is Ranitidine Hydrochloride (INN: Ranitidine), a compound defined by its ability to inhibit acid production. As an antiulcer agent, its function centers on controlling the corrosive action of acid in the stomach. Ranitidine belongs to a class of drugs that decrease the amount of acid the stomach produces. This fundamental action is clinically recognized for providing relief in scenarios where patients experience discomfort due to excessive acid. It is supplied as a single active ingredient product, concentrating its therapeutic effort on the specific molecular action of Ranitidine.

Composition, Forms, and Origin

Ranitidine is a synthetic compound, meaning its structure is the result of chemical manufacturing processes. Scheinpharm Ranitidine is widely presented as an oral dosage form, most commonly as a tablet, but has also historically been available as a solution for injection for parenteral administration in controlled settings. The high-level composition of the tablet form primarily includes the Ranitidine Hydrochloride active ingredient combined with solid pharmaceutical excipients designed for stable delivery, while the solution form uses an aqueous pharmaceutical vehicle. This versatility allows the product to address different needs in acid-related conditions.

General Purpose and Fundamental Action

The general purpose of this medication is the reduction of gastric acid secretion, thereby mitigating the damaging effects associated with excessive acid in the digestive tract. Ranitidine works by reducing the amount of acid produced by the stomach. This sustained control over acid production provides a mechanism for managing the internal acid level. The fundamental action involves a targeted blockade of stimulatory signals on the gastric parietal cells, which prevents the necessary histamine signal for acid release from being completed. This selective inhibition of the H2 receptor translates directly into a core benefit: the sustained control of the acid level, providing a consistent and proactive solution for managing general acid-related conditions.

Regulatory References

  1. MedlinePlus Drug Information on Ranitidine
  2. EMA Suspension of Ranitidine Medicines
  3. Source: EMA

What side effects are possible with Scheinpharm Ranitidine?

Possible side effects and safety information

Scheinpharm Ranitidine’s safety profile, as defined by official regulatory documents, classifies adverse reactions by frequency and affected body system. Most effects are classified as Uncommon or Rare.

Frequency-Classified Adverse Reactions

Adverse reactions are reported across various System-Organ Classes. Gastrointestinal disturbances such as constipation, diarrhea, and nausea are among the Uncommon effects documented in regulatory labeling. Rare effects include headaches, skin rashes, and reversible changes in liver function tests.

Serious Adverse Reactions

Official labeling documents specific rare, but clinically significant, adverse reactions. These include severe hypersensitivity reactions (such as anaphylaxis) and specific blood and lymphatic system disorders (e.g., leukopenia, thrombocytopenia, and very rare agranulocytosis). Reports of hepatitis (hepatocellular, cholestatic, or mixed) are also classified as serious and are generally noted as reversible upon discontinuation.

Population and Contextual Safety Notes

Specific caution is noted for certain patient populations. Older adults may have an increased susceptibility to central nervous system effects, such as reversible mental confusion, particularly if they have underlying renal impairment. Clearance of the medicine is reduced in patients with significant renal insufficiency, as defined in official prescribing information. Additionally, the label advises avoiding use in patients with a history of acute porphyria. Bradycardia is a rare adverse event reported in the context of rapid intravenous administration of the injection form.

Overdose and Emergency Response

Overdose information for ranitidine hydrochloride is derived exclusively from regulatory prescribing documents, describing specific clinical manifestations and mandated emergency responses. Documented signs of overdose primarily involve the Cardiovascular system and Central Nervous System. These signs include tachycardia (rapid heart rate), hypotension (low blood pressure), and gait disturbances. Officially reported CNS effects, such as drowsiness and lethargy, have also been noted.

While rare, severe outcomes such as cardiac arrhythmias and acute CNS disturbances are associated with high-exposure cases. Regulatory guidance is explicit: if overdose is suspected or if any severe manifestations appear, patients must seek immediate medical attention and contact emergency services. Hospital monitoring and continuous clinical observation are required for management.

No specific antidote is known for ranitidine overdose. Therefore, management is officially defined as symptomatic and supportive treatment. Procedures like gastric lavage or activated charcoal may be considered. Regulatory documentation also notes that patients with impaired renal function may face greater severity of overdose manifestations due to prolonged concentrations.

Therapeutic Uses of Scheinpharm Ranitidine

Understanding Scheinpharm Ranitidine and Its Uses

Scheinpharm Ranitidine belongs to a class of medications known as histamine-2 (H2) receptor antagonists. It is primarily used to manage conditions caused by the production of excess stomach acid. By reducing the amount of acid secreted by the glands in the lining of the stomach, this medication helps alleviate discomfort and promotes the healing of the digestive tract.

Principal Therapeutic Applications

Treatment and Prevention of Ulcers

This medication is commonly used to treat active duodenal ulcers and gastric ulcers. Beyond initial treatment, it may be used at lower concentrations for maintenance therapy to reduce the risk of ulcer recurrence in certain individuals. It is also effective in managing ulcers associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).

Gastroesophageal Reflux Disease (GERD)

Scheinpharm Ranitidine is frequently utilized to address gastroesophageal reflux disease. This condition occurs when stomach acid flows back into the esophagus, leading to irritation. The medication helps manage the symptoms of acid reflux and aids in the healing of erosive esophagitis, a condition where the esophageal lining becomes inflamed or damaged.

Pathological Hypersecretory Conditions

In some instances, the body produces abnormally high levels of gastric acid due to specific medical conditions, such as Zollinger-Ellison syndrome. Ranitidine is used to manage these chronic hypersecretory states by maintaining acid production at more stable levels.

Benefits of Acid Reduction

  • Symptom Relief: By decreasing gastric acid volume, the medication helps relieve common symptoms such as heartburn, acid indigestion, and sour stomach.
  • Tissue Protection: Reducing acidity allows the lining of the esophagus and stomach time to recover from irritation or erosion.
  • Prophylactic Support: It can be used as a preventive measure for individuals prone to acid-related distress during specific physical stress or due to chronic medication requirements.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

The eligibility for using Scheinpharm Ranitidine is strictly defined by regulatory guidelines, focusing on specific health conditions, age, and the product's regulatory status.

Eligibility and Non-Eligibility

Classification Population/Condition
Contraindicated Patients with a known hypersensitivity or allergy to ranitidine or any component of the formulation. Patients with a history of acute intermittent porphyria should avoid use.
Use Restricted Patients with impaired renal function (Creatinine Clearance <50 mL/min) require careful dosage adjustment by a healthcare provider. Caution is advised in patients with hepatic dysfunction.
Age Restriction Safety and effectiveness have not been established in pediatric patients younger than 1 month for prescription use or under 12 years for over-the-counter (OTC) use. Elderly patients may experience central nervous system effects and require monitoring.
Regulatory Status The product's eligibility for use is subject to the manufacturer's compliance with acceptable N-Nitrosodimethylamine (NDMA) impurity levels. Previous product market withdrawals by global regulatory agencies (e.g., FDA, EMA) rendered most formulations ineligible for use, though some reformulated products have since been approved.

Eligibility to use Scheinpharm Ranitidine is determined by avoiding all formal contraindications and ensuring the specific product is an officially approved formulation that meets current safety standards for impurities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ranitidine is generally well-tolerated with many other medications, but certain interactions are important to be aware of. Always inform your healthcare provider about all prescription and non-prescription drugs, vitamins, herbal supplements, and other products you are currently using.

Impact on Other Medications

Since ranitidine reduces gastric acid, it can decrease the absorption of certain drugs that require an acidic environment for proper dissolution and uptake. This effect may lower the concentration and effectiveness of the co-administered drug. Examples include some HIV protease inhibitors and certain kinase inhibitors:

Drug Type Example Medications
HIV Antivirals Atazanavir
Kinase Inhibitors Dasatinib, Gefitinib

Other Notable Interactions

Ranitidine may also affect the metabolism or clearance of other medications, potentially leading to increased blood levels of the co-administered drug and a higher risk of side effects. For example, ranitidine can decrease the clearance of midazolam and, to a lesser extent, nicotine.

In diabetic patients, ranitidine may influence the blood sugar-lowering effects of some oral medications, such as glipizide. Monitoring blood glucose levels is advised if these medications are taken together.

Simultaneous administration of high-dose antacids may decrease the absorption of ranitidine itself. If you need to take an antacid, separate the administration times as directed by your healthcare professional.

Mechanism of Action

Ranitidine functions as a competitive and reversible inhibitor within the histamine-mediated signaling pathway that regulates gastric acid secretion. The mechanism-of-action is centered on the histamine H2 receptor , which is located on the basolateral membrane of the gastric parietal cells. By acting as an antagonist, Ranitidine directly binds to this receptor, preventing the endogenous ligand, histamine, from completing its necessary binding and activation sequence. This blockade of the H2 receptor modifies an early molecular step, thereby interrupting the intracellular signaling cascade that normally drives the activation of the proton pump. The primary physiological consequence of this pathway modulation is the suppression of both basal and stimulated gastric acid secretion. This action reduces the functional output of the parietal cells, leading to a downstream physiological adjustment characterized by decreased hydrogen ion concentration within the stomach lumen.

Dosage and Administration Information

How to use Scheinpharm Ranitidine: Official Administration Guidelines

This information details the administration instructions for ranitidine. It does not cover indications, mechanism, or safety information.

Approved Dosing and Routes

Scheinpharm Ranitidine is administered through Oral and Parenteral routes. Parenteral administration includes Intramuscular (IM) injection and Intravenous (IV) injection (bolus, intermittent, or continuous infusion).

Route Standard Adult Dose Frequency and Timing
Oral Tablet 150 mg or 300 mg Typically twice daily or once daily (often at bedtime)
Parenteral 50 mg IM/IV every 6 to 8 hours

Administration Requirements

  • Oral Intake: Tablets may be taken with or without food. If prescribed once daily, the dose should generally be taken after the evening meal or at bedtime.
  • IV Bolus: The 50 mg dose must be diluted (e.g., to 20 mL) and injected slowly over a minimum period of five minutes.
  • IV Infusion: The drug must be further diluted for intermittent infusion and administered over 15 to 20 minutes.

Population-Specific Adjustments

  • Renal Impairment: For adult patients with a creatinine clearance below 50 mL/min, the oral dose is typically reduced to 150 mg every 24 hours. Similarly, parenteral doses require reduction to every 18 to 24 hours.
  • Pediatric Dosing: Doses for children (1 month to 16 years) are based on body weight, such as 2 to 4 mg/kg twice daily.

Missed Dose: If a dose is missed, take the next dose at the regularly scheduled time. Do not double the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Scheinpharm Ranitidine

Evidence for Short-Term Healing of Duodenal and Gastric Ulcers

Short-term Randomized Controlled Trials (RCTs) contribute to the evidence base exploring outcomes when ranitidine was studied for adults with active ulcers. These trials examined outcomes related to physical discomfort and measured the endoscopic healing rates, focusing on mucosal repair. Findings describe patterns observed in the studies during the defined follow-up durations, typically four to eight weeks, where comparative trials and systematic reviews described patterns of healing outcomes when measured against other studied agents and placebo controls.

Evidence for Preventing Ulcer Recurrence (Maintenance Therapy)

Following initial ulcer healing, research explored whether continued administration was associated with a difference in the rate at which ulcers returned (recurrence). Long-term placebo-controlled maintenance trials were applied in studies examining patient-reported experiences regarding the maintenance of healing status over one to two years. The results apply to the specific populations observed in the studies at that time, and the long-term outcomes of use in patients whose ulcers were not related to specific bacterial infection are not fully established.

Research on Gastroesophageal Reflux Disease (GERD) and Esophagitis

Studies examined patient-reported outcomes describing perceived discomfort, such as heartburn frequency, and objective outcomes like healing rates of erosive esophagitis. Research describes measurements of mucosal healing after treatment intervals of up to twelve weeks, and also reported how symptoms evolved in the observed populations. Comparative evidence is lacking in terms of overall long-term outcomes against current therapeutic standards. Long-term effects are not fully established regarding the prevention of severe esophageal complications.

Research Gaps and Areas of Uncertainty

The evidence base is marked by several research limitation frames. Evidence quality varies across studies, and comparative evidence is lacking for many long-term outcomes against currently favored therapies. Data for certain groups remain insufficient, particularly for defining reliable outcomes and treatment patterns in specific pediatric age groups. The findings describe group patterns, not personal outcomes, and highlight what is known—and what is still uncertain.

Key Studies & References

  1. Antisecretory treatment for pediatric gastroesophageal reflux disease – a systematic review

Frequently Asked Questions (FAQ)

Common questions about Scheinpharm Ranitidine (FAQ)

Q: Is ranitidine a proton pump inhibitor (PPI)?

No, ranitidine is not classified as a proton pump inhibitor (PPI). Studies and official information indicate that ranitidine is a histamine H2 receptor antagonist, often referred to as an H2 blocker. This mechanism is different from a PPI, as ranitidine works by blocking H2 receptors to reduce the amount of acid produced by the stomach.

Q: What is the key mechanism of action of ranitidine?

According to the official product information, the key mechanism of action is the selective competitive inhibition of histamine on the H2-receptors of the parietal cells. These parietal cells are specialized cells in the stomach lining that produce and secrete gastric acid. By blocking these specific receptors, the drug aims to reduce both the total volume and the concentration of the stomach acid.

Q: What is the main compound in Scheinpharm Ranitidine?

Regulatory documents state that the main active compound in Scheinpharm Ranitidine is ranitidine. This substance is a histamine H2 receptor antagonist, which is a type of medicine that reduces stomach acid production. It may be formulated as ranitidine hydrochloride, depending on the specific product formulation.

Q: Can ranitidine treat all types of stomach or esophageal pain?

Ranitidine is specifically studied and approved for conditions where excessive stomach acid is the cause or a major contributor to the discomfort. Studies and official information indicate it is prescribed for acid-related conditions such as ulcers and reflux esophagitis. Regulatory information indicates the medicine is specifically studied and approved for conditions where acid is the primary issue.

Q: Does ranitidine treat acid reflux?

Yes, regulatory documents state that ranitidine is used to treat conditions associated with acid reflux, notably reflux esophagitis. This condition involves inflammation and damage to the esophagus caused by stomach acid flowing back up. The drug functions by reducing the amount of acid that the stomach is capable of producing.

Q: Is the therapeutic effect of ranitidine rapid or delayed?

According to the official product information, ranitidine is rapidly absorbed following oral administration. Regulatory documents indicate that the effect to reduce acid begins quickly. Clinical effects may become more noticeable over the course of two to three weeks of continuous treatment, according to regulatory data.

Q: Is Scheinpharm Ranitidine a prescription-only medicine (POM)?

Official product information indicates that Scheinpharm Ranitidine is available as a prescription-only medicine (POM) in certain dose strengths. This means that a valid doctor’s prescription is required to obtain these strengths of the medicine. The regulatory status and availability can vary based on local regulations and the dosage strength.

Q: How should I store Scheinpharm Ranitidine tablets?

Official product information states that the tablets should be stored at a temperature below 30 C to maintain their quality and effectiveness. The medicine is generally kept in its original packaging and away from high heat and moisture, as specified in the product documentation.

Q: How does ranitidine affect the amount of stomach acid?

According to the official product information, ranitidine significantly reduces the secretion of gastric acid. This reduction applies to both the acid secreted overnight and the acid released when the stomach is stimulated by triggers like food. The product information notes it lowers both the total volume of acid produced and the acid concentration.

How should Scheinpharm Ranitidine be stored and disposed of?

Storage and Disposal of Ranitidine

The storage and disposal of ranitidine products are governed by regulatory requirements intended to manage product stability and the risk of N-Nitrosodimethylamine (NDMA) impurity formation.

Official Storage Requirements

Condition Requirement
Temperature Store tablets at room temperature and generally below 30°C; keep away from excess heat and moisture (do not store in the bathroom).
Protection Store in the original container, kept tightly closed; some formulations must be protected from light in their outer carton.
Child Safety Keep the medication out of the sight and reach of children as documented in the official labeling.

Disposal Instructions

Following the market withdrawal request, consumers are advised to stop taking the product and follow the proper disposal method. This involves mixing the unused product with an unappealing substance (like coffee grounds or dirt) and placing the mixture into a sealed bag before discarding it in the trash. Ranitidine is not classified for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagCanada

Equivalent of Scheinpharm Ranitidine found in:

A-Z Index: